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Abstract 
Recovery rates in schizophrenia remain suboptimal with up to one third resistant to 
standard treatments, a population prevalence of 0.2%. Clozapine is the only 
evidenced-based treatment for treatment resistant schizophrenia (TRS), yet there are 
significant delays in its use or it may not be trialed, potentially impacting the chance 
of recovery.  Better outcomes with earlier use of clozapine may be possible. There is 
emerging evidence that early treatment resistance is not uncommon from the earliest 
stages of psychosis. In this review, we provide an update on TRS, its epidemiology 
and its management, with a specific focus on the optimal use and timing of clozapine 
and augmentation strategies for the one third of patients who do not respond to 
clozapine.  
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Introduction 
 
Schizophrenia is a chronic disorder, of variable clinical characteristics and outcome, 
reflected in the heterogeneous response to antipsychotic medication.  Approximately 
50-70% of patients with their first episode of schizophrenia (FES) will respond to the 
first antipsychotic medication prescribed, this figure falling to 20% for those who 
require a trial of a second (Agid et al., 2011).  Antipsychotic medication (excluding 
clozapine) has its greatest effect within the first two weeks and thereafter the 
improvements are more marginal (Agid et al., 2003). Despite the expansion in our 
therapeutic armamentarium over the past decades, up to one third of patients do not 
respond to non-clozapine antipsychotics (Lally et al., 2016a, Wimberley et al., 2016) 
and are described as having treatment resistant schizophrenia (TRS). 
 
Defining treatment resistance 
The concept of treatment resistant schizophrenia first appeared in the literature in the 
mid 1960s (Itil et al., 1966), but definitions remained inconsistent, rendering the 
literature difficult to interpret. A recent systematic review of randomized controlled 
trials (RCTs) in TRS identified 42 studies; of these half did not define what they 
meant by treatment resistance and only two of the 42 studies used the same criteria 
(Howes et al., 2017). International consensus guidelines on treatment resistance 
(and response) in schizophrenia were therefore developed by the Treatment 
Response and Resistance in Psychosis (TRRIP) group (Howes et al., 2017) in an 
attempt to construct a unified definition of TRS. According to these guidelines the 
following defines TRS: the presence of persistent significant symptoms in a person 
with a diagnosis of schizophrenia, who has not had a response to at least two 
antipsychotic trials of adequate dose, duration and adherence. In defining adequate 
treatment, the guidelines follow the recommendation of the National Institute of 
Clinical Excellence (NICE) and indicate that each antipsychotic treatment last for at 
least six weeks, with each drug administered at an ‘adequate’ therapeutic dosage 
(NICE., 2014), equivalent to the minimum effective dose/ target dosage (or the 
midpoint of the target range as specified in the product summary characteristics)— or 
to a daily dose equivalent to 600 mg of chlorpromazine(Leucht et al., 2016, Leucht et 
al., 2015b). In effect, this means a minimum duration of antipsychotic treatment of 12 
weeks is required before treatment resistance can be diagnosed.  
In recognition of the possibility that unrecognised treatment non-adherence may 
mimic TRS, the guidelines recommend that at least one treatment episode utilise a 
long acting injection antipsychotic formulation (depot) for at least 4 months before 
diagnosing treatment resistance. Alternatively, the use of plasma antipsychotic 
concentrations can be informative. Although not routinely used in clinical practice, a 
growing range of second generation antipsychotics have suggested therapeutic 
ranges (minimum target threshold: amisulpride 200 μg/L, aripiprazole 150 μg/L, 
olanzapine 20 μg/L, quetiapine 100 μg/L, and risperidone 20 μg/L (total risperidone 
and 9-hydroxyrisperidone))(McCutcheon et al., 2015), though in Ireland, samples 
need to be processed at UK laboratories. A recent observational study of 99 people 
referred to a TRS service identified that 35% of antipsychotic plasma concentrations 
were sub-therapeutic, and of these, a third were undetectable(McCutcheon et al., 
2018).  
Similarly, it is important not to conflate treatment non-adherence due to intolerability 
with treatment non-response and resistance. 
Factors to consider in differentiating TRS from treatment non response due to other 
causes are shown In box 1. 
Insert BOX 1 here 
 Epidemiology of TRS 
Schizophrenia has a relatively low incidence (approx. 15.2/100 000), and a lifetime 
prevalence of approximately 7/1000 (McGrath et al., 2008, Moreno-Kustner et al., 
2018). TRS is highly disabling and affects approximately 20-30% of those diagnosed 
with schizophrenia (Demjaha et al., 2017, Lally et al., 2016a, Wimberley et al., 2016). 
In Ireland with a population of approximately 5 million, given that the lifetime risk for 
schizophrenia is 0.7%, there will be approximately 35-40000 people with 
schizophrenia. A conservative estimate is that 20% (Bachmann et al., 2017) of those 
(i.e. 7000-8000) will meet the criteria for TRS. However, there is little contemporary 
epidemiological data on psychotic disorders in Ireland.  
 
Recovery and outcome in schizophrenia  
Antipsychotic treatment failure and intolerability comes with a high clinical and 
economic cost (Kennedy et al., 2014). Our systematic review and meta-analysis of 
remission (defined as an improvement in symptoms +/-  a specified duration criteria 
(e.g. >6 months) for persistence of mild or absent symptoms) and recovery (defined 
as sustained improvement in both clinical and functioning domains +/- a duration of 
sustained improvement for ≥1 years)  in 5000 people with first episode schizophrenia 
(FES), found a recovery rate of 30% (95% CI=19.7-43.6., N=12 studies) at 5 years 
follow up, with 56.0% (95% CI=47.5-64.1, N=25 studies)  meeting criteria for 
remission at 7.5 years follow up (Lally et al., 2017a). Remission and recovery rates 
may be overestimated with shorter duration of follow up, but our average length of 
follow up was 5 and 7.5 years respectively, and we did not identify that recovery 
rates decreased during periods of follow up longer than 2 years. 
This study highlighted a better long term prognosis in FES, and a more positive 
outlook for people diagnosed with schizophrenia than previously suggested, given 
that a 2013 review of outcomes in FES and multi-episode schizophrenia estimated 
that only one in seven patients attain a functional recovery (Jaaskelainen et al., 
2013). Estimates of the prevalence of TRS derived from clinical samples should be 
interpreted with this in mind; the prevalence of TRS is likely to be overestimated in 
most studies as patients with early remission and recovery may not be included.  
Although waiting until a second antipsychotic trial fails before defining a treatment 
resistant course of illness may seem arbitrary at first glance, this is supported by 
evidence indicating that the response rate drops precipitously after successive failed 
trials of medication. Approximately 70% of FEP patients remit on their first anti-
psychotic, (Agid et al., 2011) but after the second drug, the response rate drops to 
less than 5% (Kane et al., 1988). With early use of clozapine, a response of 60-70% 
can be achieved in TRS with improvement observed up to a year after initiation 
(Meltzer, 1992).  Findings from OPTiMiSE (‘Optimisation of Treatment and 
Management of Schizophrenia in Europe’), a large scale FES study investigating the 
benefits of antipsychotic switching in patients not achieving remission on first-line 
amisulpride, indicate that clozapine is effective in substantially reducing psychotic 
symptoms after 12 weeks of use, when introduced as a second- or third-line 
treatment (Kahn et al., 2018). 
 
Clinical management of TRS 
Clozapine is the only evidence-based effective treatment for TRS, as reflected in 
international guidelines (Nielsen et al., 2016), with reported clinical response in 60-
70% of patients(Agid et al., 2011, Meltzer, 1992) and meta-analyses identifying an 
overall response rate of 40%-60% (Chakos et al., 2001, Siskind et al., 2017).  
In naturalistic settings compared to no antipsychotic treatment, clozapine is 
associated with decreased rehospitalisation (Kirwan et al., 2017, Nielsen et al., 2012, 
Stroup et al., 2016, Taipale et al., 2017) and reduced hospitalisation and risk of 
relapse (Tiihonen et al., 2017). Its use is associated with reductions in comorbid 
substance use (Brunette et al., 2006), hostility and aggression (Frogley et al., 2012, 
Krakowski et al., 2006).  
Clozapine use is also associated with lower all-cause mortality(Hayes et al., 2015, 
Tiihonen et al., 2009), completed suicide (Meltzer et al., 2003, Ringback Weitoft et 
al., 2014), and self-harm (Ringback Weitoft et al., 2014, Wimberley et al., 2017). An 
important meta-analysis identified that those continuously treated with clozapine had 
lower all cause mortality over a 7 year follow up compared to those continuously 
treated with other antipsychotics (Vermeulen et al., 2018). This allies to previous 
work showing that most major side effects with clozapine can be managed without a 
need for discontinuation (Nielsen et al., 2013), and that in certain situations clozapine 
rechallenge can be successful(Lally et al., 2018, Lally et al., 2017b, Manu et al., 
2012), indicates that concerns regarding the detrimental effect of clozapine on longer 
term mortality compared to other antipsychotics may be overestimated.  
 
When to use clozapine 
In a longitudinal study of 246 people with FES, 34% met the criteria for treatment 
resistance over a five year follow up period(Lally et al., 2016a), of whom 70%, 23% 
of the total study population, were treatment resistant from illness onset. This raises 
the possibility that TRS may be a distinctive and homogenous schizophrenia 
subgroup, in line with the biological differences seen between treatment resistant and 
treatment responsive schizophrenia(Demjaha et al., 2014).  
 
The question of staging and early recognition of treatment resistance in people with 
schizophrenia is of utmost importance. Recent longitudinal data indicates that earlier 
use of clozapine and fewer pre-clozapine antipsychotic trials are associated with 
better treatment outcomes for people with TRS (Ucok et al., 2015). A retrospective 
analysis from Japan identified a critical time window of 2.8 years after illness onset, 
subsequent to which clozapine response was poorer (response rates of 82% vs 
32%)(Yoshimura et al., 2017). Emerging evidence to suggest additional benefits with 
earlier use of clozapine exists(Agid et al., 2011, Kahn et al., 2018, Lally et al., 
2016a), much earlier than the 2.8 years critical time period identified.  
 
We know that people with TRS experience delays of 4-5 years before starting 
clozapine (Howes et al., 2012). Each non-clozapine antipsychotic trial before 
clozapine is associated with a further 10% reduction in clozapine response rates 
(Nielsen et al., 2012) while in women the functional Improvement achieved with 
clozapine decreases by 15% (HRR, 0.85; 95% CI, 0.72-1.00) for each year delay to 
initiation(Kohler-Forsberg et al., 2017). Further, high dose antipsychotic 
polypharmacy is used in 36.2–65% of patients before receiving clozapine(Howes et 
al., 2012, Taylor et al., 2003, Ucok et al., 2015), which is not evidence-based 
practice, and increases the risk of adverse events. In Ireland, a retrospective analysis 
of  171 FEP cases who presented from 1995-1999, identified that 16% (n=28) 
commenced clozapine in the follow up period, with a mean delay of 6.7 years and an 
average of 4.85 antipsychotic trials prior to clozapine use(Doyle et al., 2017).  
 
Clozapine underutilisation 
Despite its superior and unique effectiveness in TRS, there is marked geographical 
variation in prescription of clozapine, which in most countries is prescribed to far 
fewer than the approximately 30% of patients who are likely to benefit from it. 
Clozapine prescription rates in people with schizophrenia vary from 2-5%(Stroup et 
al., 2014) in the US to 20-30% in the UK, Finland and New Zealand (Downs and 
Zinkler, 2007, Tiihonen et al., 2011, Wheeler, 2008). There are several possible 
reasons for deciding against starting clozapine. It is likely that the fear of side effects 
(by clinicians and patients alike) and the inconvenience of blood monitoring limit its 
uptake. Clinician unfamiliarity with the use of clozapine, complex pathways to qualify 
for clozapine use, clinician overestimation of the prevalence and severity of side 
effects and poor communication all contribute (Nielsen et al., 2010, Verdoux et al., 
2018).  
 
 
Predicting TRS / clozapine responders 
Our findings indicate that two distinct patterns of treatment resistance develop in 
patients, with the majority displaying treatment resistance from the onset, and a 
smaller subset of patients developing treatment resistance after periods of 
relapse(Lally et al., 2016a). While there is a large literature investigating predictors of 
treatment response and remission from illness onset(Carbon and Correll, 2014), 
treatment resistance has only recently been examined longitudinally as an outcome 
measure in FEP (Demjaha et al., 2017, Lally et al., 2016a).  
An early age of onset (<20 years old) and male sex are consistent predictors for TRS 
(Lally et al., 2016a).  Severity of psychotic symptoms at first contact for psychosis do 
not predict TRS, though those with TR from onset have more psychotic symptoms at 
first contact than those with emergent resistance (Lally et al., 2016a). Greater 
impairment on the Global Assessment of Functioning (GAF) scale is associated with 
an higher risk of TRS within 2 years of first schizophrenia diagnosis (Horsdal et al., 
2017). 
 
What if, at the early stages of antipsychotic treatment we could identify those patients 
likely to respond to clozapine – and those likely to have adverse effects? The 
available neuroimaging and genetic biomarkers cannot yet reliably guide the early 
use of clozapine(Lally et al., 2016b, Samanaite et al., 2018). Of 379 investigated 
gene variants, only three (DRD3 Ser9Gly, HTR2A His452Tyr, and C825T GNB3) 
have independently replicated significant findings in clozapine response prediction. 
Replicated putative central biomarkers of clozapine response include a lower ratio of 
the dopamine and serotonin metabolites, homovanillic acid (HVA) and 5-
hydroxyindoleacetic acid (5-HIAA) in the CSF. Higher prefrontal cortical volumes and 
increased prefrontal activity on imaging may predict clozapine response (Samanaite 
et al., 2018). Neuroimaging studies have indicated a potential role for glutamate in 
TRS cases compared to treatment responsive schizophrenia, with higher glutamate 
levels in the anterior cingulate cortex (Demjaha et al., 2014, Mouchlianitis et al., 
2016), and relatively normal dopamine functioning in TRS (Demjaha et al., 2012), 
with increased levels of glutamatergic metabolites in the ACC in those with TRS 
compared to controls (Demjaha et al., 2014, Iwata et al., 2018) 
 
Standardised definitions of TRS and treatment response will allow for development of 
comparable, large, homogenous samples to prospectively assess links between 
genetic and neuroimaging data and clozapine response and tolerability. Such studies 
will need to account for factors such as concurrent medication use, tobacco smoking, 
clozapine dose and plasma concentrations. The current best available clinical marker 
of TR is the careful assessment of antipsychotic non-response with assured 
adherence and tolerability. Biomarker testing to improve the predictability of 
response to clozapine is the subject of a number of multicentre/international 
collaborations, but the clinical utility of such an approach will depend on the 
emergence of an effective alternative to clozapine for people with TRS.  
 
Clozapine non-responders 
For the 30% of TRS patients who fail to respond to clozapine (Lally et al., 2016c, 
Meltzer, 1992) and the 25% in whom clozapine is discontinued due to adverse 
events (Davis et al., 2014, Mustafa et al., 2015) there is little to guide subsequent 
pharmacological strategies. If a patient were not to respond to clozapine after 3 
months of therapeutic dosing (clozapine plasma concentrations 0.35-0.5mg/L) 
(Remington et al., 2013, Schulte, 2003), then the following steps would be 
considered.  
 
INSERT BOX 2 HERE  
 
It is important to assess for and manage comorbid conditions. People with TRS have 
more co-morbid alcohol (51%) and substance abuse (51%), than those with non-TRS 
(27–35% and 28–35% respectively). While this can complicate consistency of 
adherence to clozapine, an optimised trial of clozapine may give an individual with 
TRS the best chance of successfully managing their co-morbid substance use,   
Suicidal ideation is noted in 44% of people with TRS (Kennedy et al., 2014), and it is 
important to be aware of the possibility of a co-morbid mood disorder. In clozapine 
treated patients OCD rates of 47% have been identified (Fernandez-Egea et al., 
2018),3-fold higher than in non-TRS (Swets et al., 2014), with some authors 
believing OCD to be released by clozapine use (Schirmbeck and Zink, 2012) .  
 
Clozapine augmentation strategies 
The practice of augmentation with a second antipsychotic varies, occurring in 11.7%-
72% of clozapine-treated patients(Pai and Vella, 2012, Ucok et al., 2015, Wheeler, 
2008).  A recent systematic review and meta-analysis of 46 studies reported 
improvement in total psychotic symptoms with augmentation with aripiprazole, 
fluoxetine and sodium valproate, although the quality of included studies was noted 
to be poor(Siskind et al., 2018). Single studies supporting the efficacy of paroxetine, 
duloxetine and lithium carbonate in reducing total psychotic symptoms compared to 
placebo were identified(Siskind et al., 2018). Leucht et al (2015) examined 
augmentation with Lithium in general schizophrenia and noted that response was 
limited to those with an identified affective component to their illness(Leucht et al., 
2015a). Clinical recommendations, including those in the Maudsley 
Guidelines(Taylor et al., 2018), emphasise the importance of recognising and 
treating co-occurring mood symptomatology. Overall, caution is required and other 
meta-analyses have identified that clozapine augmentation with a second 
medication, including a second antipsychotic, an antidepressant, lamotrigine, 
topiramate, or glycine was not superior to placebo in improving psychopathology 
(Correll et al., 2017, Sommer et al., 2012), while sodium valproate is highly 
teratogenic.  
 
An earlier meta-analyses of 14 RCTs of antipsychotic augmentation concluded that 
clozapine augmentation with a second antipsychotic was modestly superior to 
placebo and well tolerated (Taylor et al., 2012). However, the most recent meta-
analysis (Galling et al., 2017) focused solely on antipsychotic augmentation after a 
non-response, rather than concurrent initiation and augmentation trials and provided 
no evidence for enhanced efficacy of antipsychotic augmentation in high‐quality 
studies. Some evidence for improvement in negative symptoms with aripiprazole 
augmentation was seen. 
 
Guidelines for clozapine augmentation from 15 years ago would have favoured a trial 
of amisulpride, based largely on anecdotal evidence and pharmacodynamic 
properties of the compound, which may synergistically augment clozapine. However, 
to date there is no trial evidence to support this or indeed alternative antipsychotic 
augmentation strategies.  A recent RCT of clozapine augmentation failed to find an 
effect of amisulpride compared to placebo in reducing psychotic symptoms, although 
recruitment was underpowered (Barnes et al., 2017) and amisulpride may merit 
further investigation in larger studies. An earlier single sulpiride trial showed efficacy 
as an augmentation agent in improving total, positive and negative symptoms(Shiloh 
et al., 1997). 
 
Siskind’s recent meta-analysis identified that aripiprazole showed effects in reducing 
total psychotic symptoms, but the effect was lost when poor quality studies were 
removed(Siskind et al., 2018). The two high quality placebo controlled trials of 
aripiprazole augmentation show divergent results, with evidence for benefits for 
negative symptoms in one trial(Chang et al., 2008), and positive symptoms in a later 
trial(Muscatello et al., 2011). Aripiprazole has however shown efficacy in relation to 
weight loss when combined with clozapine (mean difference (95% CI) of -1.36 kg (-
2.35 to -0.36) (n = 3 studies; p = 0.008) (Srisurapanont et al., 2015) and is used in 
low doses to improve tolerance of clozapine.  
 
Various non-antipsychotic agents, such as antiepileptics/mood stabilizers 
(lamotrigine, topiramate, sodium valproate, lithium carbonate,), antidepressants 
(citalopram, fluoxetine, fluvoxamine, mirtazapine), glutamatergic agents (CX 516, D-
cycloserine, D-serine, glycine, sarcosine), allopurinol, memantine, telmisartan and 
tetrabenazine have been trialled as clozapine augmentation (Elkis and Buckley, 
2016, Siskind et al., 2018). Among these, sodium valproate [6 RCTs, n =430], has 
shown efficacy in reducing total psychopathology, and positive symptoms compared 
to clozapine monotherapy. Prescribing of valproate is however a problem in women 
of childbearing age, given its teratogenicity. Similar findings were reported for 
topiramate [5 RCTs, n = 270], but it is associated with a high rate of 
discontinuation(Zheng et al., 2017). Lamotrigine has shown some evidence of 
efficacy, but this effect is lost in meta-analyses when outlier studies are 
removed(Sommer et al., 2012, Zheng et al., 2017).  
 
The divergent findings from clozapine augmentation trials means that the evidence 
base does not allow for assured recommendations, or for the development of 
treatment algorithms for clozapine non- or suboptimal response. Limitations to 
studies include the variable definitions of clozapine resistance, and the dose and 
short duration of use of the antipsychotic augmentation agents.  Current evidence 
suggests that augmentation agents may need to be used for longer than the 
standard 6 week antipsychotic monotherapy trial to enhance effectiveness(Correll et 
al., 2009). It remains the case that augmentation interventions are used as individual 
patient trials and if no symptomatic improvement is seen then the medication should 
be stopped, to minimise the risk of adverse effects.  
  
 
ECT 
An intriguing finding is the relatively high response rate in clozapine non-responders 
to augmentation with electroconvulsive therapy (ECT) in open trials (Petrides et al., 
2015).  A 2005 Cochrane Review of ECT for schizophrenia noted that in treatment 
resistant psychosis, the recommended number of ECT treatments was 12-20, higher 
than in affective disorders (Tharyan and Adams, 2005). In our recent meta-analysis 
we identified a 66% response to clozapine augmentation with ECT, with an average 
of 11 treatments used(Lally et al., 2016c). To date, it is not possible to identify 
specific clinical factors that may predict response to ECT augmentation of clozapine.  
Further, the use of ECT to augment clozapine is far from standard clinical practice in 
the UK or Ireland, with the usual course of treatment being to augment with other 
medications, or the addition of psychotherapy. 
 
A note of caution is raised from a recent small single blind sham controlled trial which 
investigated the efficacy of augmenting clozapine with 12 sessions of ECT (n=13) or 
Sham ECT (n=12) in clozapine resistant schizophrenia(Melzer-Ribeiro et al., 2017). 
This pilot study did not identify a significant difference in PANSS total, positive and 
negative scores between the groups, with only one ECT treated patient having the 
40% or more reduction in PANSS scores seen in the Petrides trial, one with a 30% or 
more reduction and only 2 with a 20% or more reduction, The authors note the small 
sample size and suggest a marked placebo (Sham ECT) response likely impacted on 
the pilot study findings (Melzer-Ribeiro et al., 2017).  
 
  
Clozapine augmentation with Cognitive Behavioural Therapy  
Cognitive behavioural therapy (CBT) is widely used in patients with schizophrenia, 
especially in the treatment of positive symptoms such as delusions and 
hallucinations and in the management of associated emotional distress. A meta-
analysis of 12 RCTs of CBT use in medication resistant psychosis showed significant 
improvement in positive psychotic symptoms compared to controls, supporting the 
use of CBT as an adjunctive treatment in TRS (Burns et al., 2014). Two small 
unrandomised RCTs assessed the efficacy of CBT in clozapine non-responders, with 
benefits seen for total psychotic and general psychopathology symptoms compared 
to a befriending control intervention (total n=21) (Barretto et al., 2009), and 
improvements in positive symptoms compared to supportive therapy (total n=37) 
(Antonio Pinto et al., 1999). The recent Focusing On Clozapine Unresponsive 
Symptoms (FOCUS) randomised clinical trial is the largest and most rigorous trial of 
CBT for clozapine resistant psychosis, and failed to identify any significant 
differences in the primary outcome of Positive and Negative Syndrome Scale 
(PANSS) total score at 21 months (mean difference −0·89, 95% CI −3·32 to 1·55; 
p=0·48), between those treated with CBT and treatment as usual(Morrison et al., 
2018). This is an important null study finding and fails to support widespread use of 
CBT for clozapine augmentation in clozapine resistant schizophrenia and other 
psychotic disorders.  This study findings needs to be considered alongside the 
overall small effect size for total symptom improvement in non-TRS, and lack of 
significant benefit for positive symptoms identified in meta-analysis of RCTs  of CBT 
use(Jauhar et al., 2014).  
 
An important consideration is for carer support and family interventions for those with 
TRS. Family interventions incorporate psychotherapeutic interventions focused on 
psychoeducation, facilitating communication and supporting families in developing 
coping skills and identifying appropriate support services. Family interventions have 
shown reductions in relapse and rehospitalisation rates, and improved medication 
adherence in psychotic disorders, along with reduced expressed emotion in 
families(Pharoah et al., 2010). It is important to note that the vast majority of family 
interventions studies have not focused on TRS, highlighting an unmet need in 
research of family interventions in this patient population, and for practice 
implementation. 
 
Affective symptoms 
Co-morbid mood disorders are often missed in treatment resistance but are 
important to bear in mind, and if co-morbid depression is present, whether it is 
historically in a unipolar or bipolar context. Meta-analytic data exists to support 
antidepressant augmentation of FGAs in non-TRS patients with predominant 
negative symptoms. The strongest evidence is for augmentation with SSRIs, 
although there is low-level evidence for the use of augmentation with mirtazapine 
with improvements on positive symptom severity(Galling et al., 2018)   
In a meta-analysis of non-TR schizophrenia cases, a significant risk difference was 
found in favour of antidepressant treatment, with a number needed to treat of 5 (95% 
CI 4–9), but the effect did not persist after sensitivity analysis(Gregory et al., 2017). It 
is worth noting that the bulk of the agents showing effectiveness in clozapine 
augmentation in the Siskind et al (2018) meta-analysis were antidepressants or 
mood stabilisers, although the presence or absence of affective disorder was not 
included as a variable in the analysis.  
 
Negative symptoms 
To date, no pharmacological strategies have demonstrated consistently replicable 
effects on primary negative symptoms.  However, there is scope for better outcomes, 
particularly in negative symptoms secondary to depression, positive psychotic 
symptoms, or motor side effects, which may be more amenable to treatment, and for 
which clozapine treatment may have advantages.  
 
Clozapine refusal 
 
Patients sometimes refuse clozapine due to dislike of phlebotomy or needle phobia. 
Possible strategies may include the use of the smallest calibre needles, the 
application of EMLA cream prior to phlebotomy, and consideration for the use of 
psychological interventions based on exposure techniques where appropriate. 
 
An alternative strategy is the use of finger prick capillary blood sampling. This could 
be considered if all attempts to perform venous sampling fail.  A single puncture site 
on the palmar surface of the distal phalanx of the 3rd or 4th digit is used, with the first 
drop of blood discarded before collecting a volume of approximately 125-250 uL 
(approximately 4-5 drops of blood).  Prior discussion with the local haematology 
laboratory is essential to ensure that granulocyte counts can be reliably measured 
from a capillary sample as this is not standard and confirmation with the clozapine 
regulatory body is needed (e.g. ZTAS or CPMS).  
 
Intramuscular (IM) clozapine is an unlicensed product that has been used as a short-
term intervention to potentially enable the initiation of clozapine in those who are 
refusing oral administration.  It is started with a view to establishing regular oral 
clozapine as soon as possible, and clozapine tablets are offered to the patient as an 
alternative before each injection. Current formulations of clozapine IM, are 25mg/ml 
and each ampoule contains 5mls (125mg). The maximum single IM dose is 100mg, 
administered in the gluteal muscle, which restricts the potential for dose escalation. 
In an Israeli retrospective analysis of the use of parenteral clozapine in 59 clozapine 
treated patients who became noncompliant, 27% (n=16) were switched to oral 
clozapine within 3 days, and a further 71% (n=42) by 7 days. One patient continued 
with IM clozapine for 8 days. There were no adverse events reported, though 
patients were already established on clozapine for ‘a few weeks’ prior to the use of 
parenteral clozapine (Lokshin et al., 1999). Seventeen patients with TRS were 
identified for treatment with IM clozapine in a Dutch cohort(Schulte et al., 2007), of 
whom ten started IM injections, while 7 chose oral clozapine in preference. The 
duration of IM treatment was one to four days for four patients (40%), seven to 
eleven days for three patients (30%), and one to three months for three patients 
(30%). The maximum daily dosage of IM clozapine, given in one or two injections, 
was 12.5 to 25 mg for four patients, and 50 mg, 150 mg, 200 mg, 225 mg, 300 mg 
and 500 mg for six patients respectively (the mg/ml dose used was not provided). 
Clozapine was discontinued in two patients, one who developed leucopenia, and 
another who developed impaired liver function. A further patient continued IM 
treatment for 90 days without any evidence that they would switch to oral clozapine, 
necessitating the ending of the IM regimen(Schulte et al., 2007).   
 
Alternatives to clozapine in TRS 
As clozapine may not be suitable for some patients e.g. due to intolerability, adverse 
events or if they are deemed to be non-rechallengeable, alternative treatments for 
TRS have been tried. The best evidence is for the use of high dose olanzapine with 
some trial data (olanzapine mean dose 35mg (Meltzer et al., 2008); mean olanzapine 
dose of 20.5 mg and 67% treated with 25mg/day) (Tollefson et al., 2001) providing 
support for equivalent reductions in psychotic symptoms and relapses in comparison 
to clozapine. Of note, while Meltzer et al (2008) found an equivalent reduction in 
PANSS score on high dose olanzapine, those randomized to clozapine had better 
function and fewer emergent cardiometabolic risk factors.  Other trials found high 
dose olanzapine to be inferior to clozapine in adults (mean olanzapine dose 
50mg/day) (Conley et al., 2003) and adolescents (mean olanzapine dose 
26.2mg/day) (Kumra et al., 2008).  
 
Meta-analysis of antipsychotic augmentation with the selective oestrogen receptor 
modulator (SERM) raloxifene in non-TR schizophrenia suggests that it is useful in 
improving symptoms compared to placebo(de Boer et al., 2018). In a RCT of 56 
postmenopausal women with TRS, raloxifene at 120mg/day was associated with  a 
greater reduction in PANSS total score relative to placebo (β = -6.37; 95%CI, -11.64 
to -1.10; P = .02) and an increased probability of clinical response (hazard ratio, 5.79; 
95%CI, 1.46 to 22.97; P = .01)(Kulkarni et al., 2016). Raloxifene was well tolerated 
and offers potential for its use in this difficult to treat patient cohort and follows on 
previous trials from the same centre showing an effect of adjunctive oestradiol 
200mcg in symptom improvement, particularly positive symptoms(Kulkarni et al., 
2015). However, other studies have failed to find a benefit for adjunctive raloxifene in 
improving cognitive symptoms in non-TR schizophrenia(Kulkarni et al., 2016, Weiser 
et al., 2017), or in improving symptom severity(Weiser et al., 2017).  
Key areas for clinical and academic focus to optimise the management of TRS are 
outlined in Box 3. 
 
PLEASE INSERT BOX 3 Here 
 
 
Conclusion 
The evidence highlights clozapine as the cornerstone of the pharmacological 
management of TRS.  Clozapine is a uniquely effective medication with over half of 
those treated responding and with additional benefits in reducing suicide, aggression, 
violence, alcohol and substance abuse, psychiatric rehospitalisation and all-cause 
mortality. Despite there being no comparable alternatives, clozapine remains 
underutilised and initiation is delayed. Increasing evidence suggests that it should be 
used earlier in the course of illness, with better longer term outcomes associated with 
earlier use.  
Despite being available for over 25 years, the incorporation of clozapine initiation into 
routine practice needs more work. Although non-clozapine antipsychotics confer little 
or no benefit for a third of all people with schizophrenia, TRS remains a poor relation 
in the academic community, with a comparative paucity of studies on its 
epidemiology, genetic, molecular and neuroimaging characteristics, and the 
response to pharmacotherapeutic/psychotherapeutic interventions.   
With no current credible therapeutic alternatives, it is worth considerable investment 
in clinical services and academic structures to optimise our use and understanding of 
clozapine and of strategies, which may help when clozapine fails or is not, tolerated. 
It is important to maintain an awareness of the high rates of co-morbidity in TRS, 
acknowledging that addressing these may considerably improve function or quality of 
life in someone for whom antipsychotics are having little effect.  Novel 
psychotherapeutic approaches, such as Avatar Therapy may also hold potential.  As 
TRS research is now moving more into the personalised sphere, this opens the 
possibility of identifying effective interventions for subgroups of people with TRS. In 
the meantime, collaborations between clinicians, academics, service users, families, 
service-planners and industry are needed to scan the horizon for future 
developments in the prevention and management of TRS. 
 
 
References 
 
Agid, O, Arenovich, T, Sajeev, G, Zipursky, RB, Kapur, S, Foussias, G & 
Remington, G (2011). An algorithm-based approach to first-episode schizophrenia: 
response rates over 3 prospective antipsychotic trials with a retrospective data 
analysis. Journal of Clinical Psychiatry 72, 1439-44. 
Agid, O, Kapur, S, Arenovich, T & Zipursky, RB (2003). Delayed-onset hypothesis 
of antipsychotic action: a hypothesis tested and rejected. Archives of General 
Psychiatry 60, 1228-35. 
Antonio Pinto, Silvestro La Pia, Rosa Mennella, Domenico Giorgio & Luigi 
DeSimone (1999). Rehab Rounds: Cognitive-Behavioral Therapy and Clozapine for 
Clients With Treatment-Refractory Schizophrenia. Psychiatric Services 50, 901-904. 
Bachmann, CJ, Aagaard, L, Bernardo, M, Brandt, L, Cartabia, M, Clavenna, A, 
Coma Fuste, A, Furu, K, Garuoliene, K, Hoffmann, F, Hollingworth, S, 
Huybrechts, KF, Kalverdijk, LJ, Kawakami, K, Kieler, H, Kinoshita, T, Lopez, 
SC, Machado-Alba, JE, Machado-Duque, ME, Mahesri, M, Nishtala, PS, Piovani, 
D, Reutfors, J, Saastamoinen, LK, Sato, I, Schuiling-Veninga, CCM, Shyu, YC, 
Siskind, D, Skurtveit, S, Verdoux, H, Wang, LJ, Zara Yahni, C, Zoega, H & 
Taylor, D (2017). International trends in clozapine use: a study in 17 countries. Acta 
Psychiatrica Scandinavica 136, 37-51. 
Barnes, TR, Leeson, VC, Paton, C, Marston, L, Davies, L, Whittaker, W, Osborn, 
D, Kumar, R, Keown, P, Zafar, R, Iqbal, K, Singh, V, Fridrich, P, Fitzgerald, Z, 
Bagalkote, H, Haddad, PM, Husni, M & Amos, T (2017). Amisulpride augmentation 
in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-
controlled, randomised trial of clinical effectiveness and cost-effectiveness. Health 
Technology Assessment 21, 1-56. 
Barretto, EM, Kayo, M, Avrichir, BS, Sa, AR, Camargo, M, Napolitano, IC, Nery, 
FG, Pinto, JA, Jr., Bannwart, S, Scemes, S, Di Sarno, E & Elkis, H (2009). A 
preliminary controlled trial of cognitive behavioral therapy in clozapine-resistant 
schizophrenia. Journal of Nervous and Mental Disease 197, 865-8. 
Brunette, MF, Drake, RE, Xie, H, McHugo, GJ & Green, AI (2006). Clozapine use 
and relapses of substance use disorder among patients with co-occurring 
schizophrenia and substance use disorders. Schizophrenia Bulletin 32, 637-43. 
Burns, A, Erickson, H & Brenner, C (2014). Cognitive-Behavioral Therapy for 
Medication-Resistant Psychosis: A Meta-Analytic Review. Psychiatric Services 65, 
874-880. 
Carbon, M & Correll, CU (2014). Clinical predictors of therapeutic response to 
antipsychotics in schizophrenia. Dialogues in clinical neuroscience 16, 505-24. 
Chakos, M, Lieberman, J, Hoffman, E, Bradford, D & Sheitman, B (2001). 
Effectiveness of second-generation antipsychotics in patients with treatment-resistant 
schizophrenia: a review and meta-analysis of randomized trials. American Journal of 
Psychiatry 158, 518-26. 
Chang, JS, Ahn, YM, Park, HJ, Lee, KY, Kim, SH, Kang, UG & Kim, YS (2008). 
Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: 
an 8-week, randomized, double-blind, placebo-controlled trial. Journal of Clinical 
Psychiatry 69, 720-31. 
Conley, RR, Kelly, DL, Richardson, CM, Tamminga, CA & Carpenter, WT, Jr. 
(2003). The efficacy of high-dose olanzapine versus clozapine in treatment-resistant 
schizophrenia: a double-blind crossover study. Journal of Clinical 
Psychopharmacology 23, 668-71. 
Correll, CU, Rubio, JM, Inczedy-Farkas, G, Birnbaum, ML, Kane, JM & Leucht, S 
(2017). Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic 
Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the 
Meta-analytic Evidence. JAMA Psychiatry 74, 675-684. 
Correll, CU, Rummel-Kluge, C, Corves, C, Kane, JM & Leucht, S (2009). 
Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of 
randomized controlled trials. Schizophrenia Bulletin 35, 443-57. 
Davis, MC, Fuller, MA, Strauss, ME, Konicki, PE & Jaskiw, GE (2014). 
Discontinuation of clozapine: a 15-year naturalistic retrospective study of 320 
patients. Acta Psychiatrica Scandinavica 130, 30-9. 
de Boer, J, Prikken, M, Lei, WU, Begemann, M & Sommer, I (2018). The effect of 
raloxifene augmentation in men and women with a schizophrenia spectrum disorder: 
a systematic review and meta-analysis. npj Schizophrenia 4, 1. 
Demjaha, A, Egerton, A, Murray, RM, Kapur, S, Howes, OD, Stone, JM & 
McGuire, PK (2014). Antipsychotic treatment resistance in schizophrenia associated 
with elevated glutamate levels but normal dopamine function. Biological Psychiatry 
75, e11-3. 
Demjaha, A, Lappin, JM, Stahl, D, Patel, MX, MacCabe, JH, Howes, OD, Heslin, 
M, Reininghaus, UA, Donoghue, K, Lomas, B, Charalambides, M, Onyejiaka, A, 
Fearon, P, Jones, P, Doody, G, Morgan, C, Dazzan, P & Murray, RM (2017). 
Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes 
and predictors. Psychological Medicine 47, 1981-1989. 
Demjaha, A, Murray, RM, McGuire, PK, Kapur, S & Howes, OD (2012). Dopamine 
synthesis capacity in patients with treatment-resistant schizophrenia. American 
Journal of Psychiatry 169, 1203-10. 
Downs, J & Zinkler, M (2007). Clozapine: national review of postcode prescribing. 
The Psychiatrist 31, 384-387. 
Doyle, R, Behan, C, O'Keeffe, D, Masterson, S, Kinsella, A, Kelly, A, Sheridan, 
A, Keating, D, Hynes, C, Madigan, K, Lawlor, E & Clarke, M (2017). Clozapine 
Use in a Cohort of First-Episode Psychosis. J Clin Psychopharmacol 37, 512-517. 
Elkis, H & Buckley, PF (2016). Treatment-Resistant Schizophrenia. Psychiatric 
Clinics of North America 39, 239-65. 
Fernandez-Egea, E, Worbe, Y, Bernardo, M & Robbins, TW (2018). Distinct risk 
factors for obsessive and compulsive symptoms in chronic schizophrenia. 
Psychological Medicine 19, 1-8. 
Frogley, C, Taylor, D, Dickens, G & Picchioni, M (2012). A systematic review of 
the evidence of clozapine's anti-aggressive effects. International Clinical 
Psychopharmacology 15, 1351-71. 
Galling, B, Roldan, A, Hagi, K, Rietschel, L, Walyzada, F, Zheng, W, Cao, XL, 
Xiang, YT, Zink, M, Kane, JM, Nielsen, J, Leucht, S & Correll, CU (2017). 
Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, 
meta-analysis and meta-regression analysis. World Psychiatry 16, 77-89. 
Galling, B, Vernon, JA, Pagsberg, AK, Wadhwa, A, Grudnikoff, E, Seidman, AJ, 
Tsoy-Podosenin, M, Poyurovsky, M, Kane, JM & Correll, CU (2018). Efficacy and 
safety of antidepressant augmentation of continued antipsychotic treatment in 
patients with schizophrenia. Acta Psychiatrica Scandinavica 137, 187-205. 
Gregory, A, Mallikarjun, P & Upthegrove, R (2017). Treatment of depression in 
schizophrenia: systematic review and meta-analysis. British Journal of Psychiatry 
211, 198-204. 
Hayes, RD, Downs, J, Chang, CK, Jackson, RG, Shetty, H, Broadbent, M, 
Hotopf, M & Stewart, R (2015). The effect of clozapine on premature mortality: an 
assessment of clinical monitoring and other potential confounders. Schizophrenia 
Bulletin 41, 644-55. 
Horsdal, HT, Wimberley, T, Kohler-Forsberg, O, Baandrup, L & Gasse, C (2017). 
Association between global functioning at first schizophrenia diagnosis and treatment 
resistance. Early Intervention Psychiatry. 
Howes, OD, McCutcheon, R, Agid, O, de Bartolomeis, A, van Beveren, NJ, 
Birnbaum, ML, Bloomfield, MA, Bressan, RA, Buchanan, RW, Carpenter, WT, 
Castle, DJ, Citrome, L, Daskalakis, ZJ, Davidson, M, Drake, RJ, Dursun, S, 
Ebdrup, BH, Elkis, H, Falkai, P, Fleischacker, WW, Gadelha, A, Gaughran, F, 
Glenthoj, BY, Graff-Guerrero, A, Hallak, JE, Honer, WG, Kennedy, J, Kinon, BJ, 
Lawrie, SM, Lee, J, Leweke, FM, MacCabe, JH, McNabb, CB, Meltzer, H, Moller, 
HJ, Nakajima, S, Pantelis, C, Reis Marques, T, Remington, G, Rossell, SL, 
Russell, BR, Siu, CO, Suzuki, T, Sommer, IE, Taylor, D, Thomas, N, Ucok, A, 
Umbricht, D, Walters, JT, Kane, J & Correll, CU (2017). Treatment-Resistant 
Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working 
Group Consensus Guidelines on Diagnosis and Terminology. American Journal of 
Psychiatry 174, 216-229. 
Howes, OD, Vergunst, F, Gee, S, McGuire, P, Kapur, S & Taylor, D (2012). 
Adherence to treatment guidelines in clinical practice: study of antipsychotic 
treatment prior to clozapine initiation. British Journal of Psychiatry 201, 481-5. 
Itil, TM, Keskiner, A & Fink, M (1966). Therapeutic studies in "therapy resistant" 
schizophrenic patients. Comprehensive Psychiatry 7, 488-93. 
Iwata, Y, Nakajima, S, Plitman, E, Caravaggio, F, Kim, J, Shah, P, Mar, W, 
Chavez, S, De Luca, V, Mimura, M, Remington, G, Gerretsen, P & Graff-
Guerrero, A (2018). Glutamatergic Neurometabolite Levels in Patients with Ultra 
Treatment-Resistant Schizophrenia: a Cross-sectional 3T Proton MRS study. 
Biological Psychiatry. 
Jaaskelainen, E, Juola, P, Hirvonen, N, McGrath, JJ, Saha, S, Isohanni, M, 
Veijola, J & Miettunen, J (2013). A systematic review and meta-analysis of recovery 
in schizophrenia. Schizophrenia Bulletin 39, 1296-306. 
Jauhar, S, McKenna, PJ, Radua, J, Fung, E, Salvador, R & Laws, KR (2014). 
Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review 
and meta-analysis with examination of potential bias. British Journal of Psychiatry 
204, 20-9. 
Kahn, RS, Winter van Rossum, I, Leucht, S, McGuire, P, Lewis, SW, Leboyer, M, 
Arango, C, Dazzan, P, Drake, R, Heres, S, Díaz-Caneja, CM, Rujescu, D, Weiser, 
M, Galderisi, S, Glenthøj, B, Eijkemans, MJC, Fleischhacker, WW, Kapur, S, 
Sommer, IE, Kahn, RS, Sommer, IE, Winter-van Rossum, I, Somers, M, Ywema, 
PC, Kapur, S, McGuire, P, Leboyer, M, Meyer-Lindenberg, A, Lewis, SW, 
Leucht, S, Arango, C, Fleischhacker, WW, Meijering, AL, Petter, J, Van de Brug, 
R, Schotsman, J, Zwerver, J, Peuskens, J, De Hert, M, Thys, E, Hranov, LG, 
Hranov, V, Libiger, J, Köhler, R, Mohr, P, Glenthoj, B, Broberg, B, Düring, S, 
Baandrup, L, Jamain, S, Heres, S, Rujescu, D, Giegling, I, Weiser, M, Bar Heim, 
M, Davidson, M, Galderisi, S, Bucci, P, Mucci, A, Rybakowski, J, Remlinger-
Molenda, A, Gonen, I, Radu, P, Díaz-Marsá, M, Rodriguez, A, Palomo, T, 
Rodriguez-Jimenez, R, García-Portilla, P, Bernardo, M, Bobes, J, Vilares 
Oliveira, C, Berger, G, Wildt, C, Dazzan, P, Perez-Iglesias, R, Drake, R, Gregory, 
S, Wilson, D, Díaz-Caneja, CM & Eijkemans, MJC (2018). Amisulpride and 
olanzapine followed by open-label treatment with clozapine in first-episode 
schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching 
study. The Lancet Psychiatry. 
Kane, J, Honigfeld, G, Singer, J & Meltzer, H (1988). Clozapine for the treatment-
resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of 
General Psychiatry 45, 789-96. 
Kennedy, JL, Altar, CA, Taylor, DL, Degtiar, I & Hornberger, JC (2014). The 
social and economic burden of treatment-resistant schizophrenia: a systematic 
literature review. International Clinical Psychopharmacology 29, 63-76. 
Kirwan, P, O’Connor, L, Sharma, K & McDonald, C (2017). The impact of 
switching to clozapine on psychiatric hospital admissions: a mirror-image study. Irish 
Journal of Psychological Medicine, 1-5. 
Kohler-Forsberg, O, Horsdal, HT, Legge, SE, MacCabe, JH & Gasse, C (2017). 
Predictors of Nonhospitalization and Functional Response in Clozapine Treatment: A 
Nationwide, Population-Based Cohort Study. Journal of Clinical 
Psychopharmacology 37, 148-154. 
Krakowski, MI, Czobor, P, Citrome, L, Bark, N & Cooper, TB (2006). Atypical 
antipsychotic agents in the treatment of violent patients with schizophrenia and 
schizoaffective disorder. Archives of General Psychiatry 63, 622-9. 
Kulkarni, J, Gavrilidis, E, Gwini, SM, Worsley, R, Grigg, J, Warren, A, Gurvich, 
C, Gilbert, H, Berk, M & Davis, SR (2016). Effect of adjunctive raloxifene therapy on 
severity of refractory schizophrenia in women: A randomized clinical trial. JAMA 
Psychiatry 73, 947-954. 
Kulkarni, J, Gavrilidis, E, Wang, W, Worsley, R, Fitzgerald, PB, Gurvich, C, Van 
Rheenen, T, Berk, M & Burger, H (2015). Estradiol for treatment-resistant 
schizophrenia: a large-scale randomized-controlled trial in women of child-bearing 
age. Molecular Psychiatry 20, 695-702. 
Kumra, S, Kranzler, H, Gerbino-Rosen, G, Kester, HM, DeThomas, C, 
Kafantaris, V, Correll, CU & Kane, JM (2008). Clozapine and "High-Dose" 
Olanzapine in Refractory Early-Onset Schizophrenia: A 12-Week Randomized and 
Double-Blind Comparison. Biological Psychiatry 63, 524-529. 
Lally, J, Ajnakina, O, Di Forti, M, Trotta, A, Demjaha, A, Kolliakou, A, Mondelli, 
V, Reis Marques, T, Pariante, C, Dazzan, P, Shergil, SS, Howes, OD, David, AS, 
MacCabe, JH, Gaughran, F & Murray, RM (2016a). Two distinct patterns of 
treatment resistance: clinical predictors of treatment resistance in first-episode 
schizophrenia spectrum psychoses. Psychological Medicine 46, 3231-3240. 
Lally, J, Ajnakina, O, Stubbs, B, Cullinane, M, Murphy, KC, Gaughran, F & 
Murray, RM (2017a). Remission and recovery from first-episode psychosis in adults: 
systematic review and meta-analysis of long-term outcome studies. British Journal of 
Psychiatry 211, 350-358. 
Lally, J, Al Kalbani, H, Krivoy, A, Murphy, KC, Gaughran, F & MacCabe, JH 
(2018). Hepatitis, Interstitial Nephritis, and Pancreatitis in Association With Clozapine 
Treatment: A Systematic Review of Case Series and Reports. Journal of Clinical 
Psychopharmacology 38, 520-527. 
Lally, J, Gaughran, F, Timms, P & Curran, SR (2016b). Treatment-resistant 
schizophrenia: current insights on the pharmacogenomics of antipsychotics. 
Pharmgenomics and Personalized Medicine 9, 117-129. 
Lally, J, Malik, S, Krivoy, A, Whiskey, E, Taylor, DM, Gaughran, FP, Flanagan, 
RJ, Mijovic, A & MacCabe, JH (2017b). The Use of Granulocyte Colony-Stimulating 
Factor in Clozapine Rechallenge: A Systematic Review. Journal of Clinical 
Psychopharmacology 37, 600-604. 
Lally, J, Tully, J, Robertson, D, Stubbs, B, Gaughran, F & MacCabe, JH (2016c). 
Augmentation of clozapine with electroconvulsive therapy in treatment resistant 
schizophrenia: A systematic review and meta-analysis. Schizophrenia Research 171, 
215-24. 
Leucht, S, Helfer, B, Dold, M, Kissling, W & McGrath, JJ (2015a). Lithium for 
schizophrenia. Cochrane Database of Systematic Reviews, Cd003834. 
Leucht, S, Samara, M, Heres, S & Davis, JM (2016). Dose Equivalents for 
Antipsychotic Drugs: The DDD Method. Schizophrenia Bulletin 42 Suppl 1, S90-4. 
Leucht, S, Samara, M, Heres, S, Patel, MX, Furukawa, T, Cipriani, A, Geddes, J 
& Davis, JM (2015b). Dose Equivalents for Second-Generation Antipsychotic Drugs: 
The Classical Mean Dose Method. Schizophrenia Bulletin 41, 1397-402. 
Lokshin, P, Lerner, V, Miodownik, C, Dobrusin, M & Belmaker, RH (1999). 
Parenteral clozapine: five years of experience. Journal of Clinical 
Psychopharmacology 19, 479-80. 
Manu, P, Sarpal, D, Muir, O, Kane, JM & Correll, CU (2012). When can patients 
with potentially life-threatening adverse effects be rechallenged with clozapine? A 
systematic review of the published literature. Schizophrenia Research 134, 180-186. 
McCutcheon, R, Beck, K, Bloomfield, MA, Marques, TR, Rogdaki, M & Howes, 
OD (2015). Treatment resistant or resistant to treatment? Antipsychotic plasma 
levels in patients with poorly controlled psychotic symptoms. Journal of 
Psychopharmacology 29, 892-7. 
McCutcheon, R, Beck, K, D'Ambrosio, E, Donocik, J, Gobjila, C, Jauhar, S, 
Kaar, S, Pillinger, T, Reis Marques, T, Rogdaki, M & Howes, OD (2018). 
Antipsychotic plasma levels in the assessment of poor treatment response in 
schizophrenia. Acta Psychiatrica Scandinavica 137, 39-46. 
McGrath, J, Saha, S, Chant, D & Welham, J (2008). Schizophrenia: a concise 
overview of incidence, prevalence, and mortality. Epidemiologic Reviews 30, 67-76. 
Meltzer, HY (1992). Treatment of the neuroleptic-nonresponsive schizophrenic 
patient. Schizophrenia Bulletin 18, 515-42. 
Meltzer, HY, Alphs, L, Green, AI, Altamura, AC, Anand, R, Bertoldi, A, 
Bourgeois, M, Chouinard, G, Islam, MZ, Kane, J, Krishnan, R, Lindenmayer, JP 
& Potkin, S (2003). Clozapine treatment for suicidality in schizophrenia: International 
Suicide Prevention Trial (InterSePT). Archives of General Psychiatry 60, 82-91. 
Meltzer, HY, Bobo, WV, Roy, A, Jayathilake, K, Chen, Y, Ertugrul, A, Anil 
Yagcioglu, AE & Small, JG (2008). A randomized, double-blind comparison of 
clozapine and high-dose olanzapine in treatment-resistant patients with 
schizophrenia. Journal of Clinical Psychiatry 69, 274-85. 
Melzer-Ribeiro, DL, Rigonatti, SP, Kayo, M, Avrichir, BS, Ribeiro, RB, Santos, 
BD, Fortes, M & Elkis, H (2017). Efficacy of electroconvulsive therapy augmentation 
for partial response to clozapine: a pilot randomized ECT   sham controlled trial. 
Archives of Clinical Psychiatry (São Paulo) 44, 45-50. 
Moreno-Kustner, B, Martin, C & Pastor, L (2018). Prevalence of psychotic 
disorders and its association with methodological issues. A systematic review and 
meta-analyses. PLoS One 13, e0195687. 
Morrison, AP, Pyle, M, Gumley, A, Schwannauer, M, Turkington, D, MacLennan, 
G, Norrie, J, Hudson, J, Bowe, SE, French, P, Byrne, R, Syrett, S, Dudley, R, 
McLeod, HJ, Griffiths, H, Barnes, TRE, Davies, L, Kingdon, D, Aydinlar, S, 
Courtley, J, Douglas-Bailey, M, Graves, E, Holden, N, Hutton, J, Hutton, P, 
Irving, S, Jackson, C, Lebert, T, Mander, H, McCartney, L, Munro-Clark, T, 
Murphy, EK, Spanswick, M, Steele, A, Tip, L & Tully, S (2018). Cognitive 
behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-
blinded, randomised controlled trial. The Lancet Psychiatry. 
Mouchlianitis, E, Bloomfield, MA, Law, V, Beck, K, Selvaraj, S, Rasquinha, N, 
Waldman, A, Turkheimer, FE, Egerton, A, Stone, J & Howes, OD (2016). 
Treatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate 
Cortex Glutamate Compared to Treatment-Responsive. Schizophrenia Bulletin 42, 
744-52. 
Muscatello, MR, Bruno, A, Pandolfo, G, Mico, U, Scimeca, G, Di Nardo, F, 
Santoro, V, Spina, E & Zoccali, RA (2011). Effect of aripiprazole augmentation of 
clozapine in schizophrenia: a double-blind, placebo-controlled study. Schizophrenia 
Research 127, 93-9. 
Mustafa, FA, Burke, JG, Abukmeil, SS, Scanlon, JJ & Cox, M (2015). 
"Schizophrenia past Clozapine": Reasons for Clozapine Discontinuation, Mortality, 
and Alternative Antipsychotic Prescribing. Pharmacopsychiatry 48, 11-4. 
NICE. (2014). Psychosis and schizophrenia in adults: treatment and management 
(Clinical guideline 178). Royal College of Psychiatrists: London. 
Nielsen, J, Correll, CU, Manu, P & Kane, JM (2013). Termination of clozapine 
treatment due to medical reasons: when is it warranted and how can it be avoided? 
Journal of Clinical Psychiatry 74, 603-13. 
Nielsen, J, Dahm, M, Lublin, H & Taylor, D (2010). Psychiatrists' attitude towards 
and knowledge of clozapine treatment. Journal of Psychopharmacology 24, 965-71. 
Nielsen, J, Nielsen, RE & Correll, CU (2012). Predictors of clozapine response in 
patients with treatment-refractory schizophrenia: results from a Danish Register 
Study. Journal of Clinical Psychopharmacology 32, 678-83. 
Nielsen, J, Young, C, Ifteni, P, Kishimoto, T, Xiang, YT, Schulte, PF, Correll, CU 
& Taylor, D (2016). Worldwide Differences in Regulations of Clozapine Use. CNS 
Drugs 30, 149-61. 
Pai, NB & Vella, SC (2012). Reason for clozapine cessation. Acta Psychiatrica 
Scandinavica 125, 39-44. 
Petrides, G, Malur, C, Braga, RJ, Bailine, SH, Schooler, NR, Malhotra, AK, Kane, 
JM, Sanghani, S, Goldberg, TE, John, M & Mendelowitz, A (2015). 
Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a 
prospective, randomized study. American Journal of Psychiatry 172, 52-8. 
Pharoah, F, Mari, J, Rathbone, J & Wong, W (2010). Family intervention for 
schizophrenia. Cochrane Database of Systematic Reviews, Cd000088. 
Remington, G, Agid, O, Foussias, G, Ferguson, L, McDonald, K & Powell, V 
(2013). Clozapine and therapeutic drug monitoring: is there sufficient evidence for an 
upper threshold? Psychopharmacology (Berl) 225, 505-18. 
Ringback Weitoft, G, Berglund, M, Lindstrom, EA, Nilsson, M, Salmi, P & 
Rosen, M (2014). Mortality, attempted suicide, re-hospitalisation and prescription 
refill for clozapine and other antipsychotics in Sweden-a register-based study. 
Pharmacoepidemiology and Drug Safety 23, 290-8. 
Samanaite, R, Gillespie, A, Sendt, KV, McQueen, G, MacCabe, JH & Egerton, A 
(2018). Biological Predictors of Clozapine Response: A Systematic Review. Frontiers 
in Psychiatry 9, 327. 
Schirmbeck, F & Zink, M (2012). Clozapine-induced obsessive-compulsive 
symptoms in schizophrenia: a critical review. Curr Neuropharmacol 10, 88-95. 
Schulte, P (2003). What is an adequate trial with clozapine?: therapeutic drug 
monitoring and time to response in treatment-refractory schizophrenia. Clin 
Pharmacokinet 42, 607-18. 
Schulte, PFJ, Stienen, JJ, Bogers, J, Cohen, D, van Dijk, D, Lionarons, WH, 
Sanders, SS & Heck, AH (2007). Compulsory treatment with clozapine: A 
retrospective long-term cohort study. International Journal of Law and Psychiatry 30, 
539-545. 
Shiloh, R, Zemishlany, Z, Aizenberg, D, Radwan, M, Schwartz, B, Dorfman-
Etrog, P, Modai, I, Khaikin, M & Weizman, A (1997). Sulpiride augmentation in 
people with schizophrenia partially responsive to clozapine. A double-blind, placebo-
controlled study. British Journal of Psychiatry 171, 569-73. 
Siskind, D, Siskind, V & Kisely, S (2017). Clozapine Response Rates among 
People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and 
Meta-Analysis. Canadian Journal of Psychiatry 62, 772-777. 
Siskind, DJ, Lee, M, Ravindran, A, Zhang, Q, Ma, E, Motamarri, B & Kisely, S 
(2018). Augmentation strategies for clozapine refractory schizophrenia: A systematic 
review and meta-analysis. Aust N Z J Psychiatry 52, 751-767. 
Sommer, IE, Begemann, MJ, Temmerman, A & Leucht, S (2012). 
Pharmacological augmentation strategies for schizophrenia patients with insufficient 
response to clozapine: a quantitative literature review. Schizophrenia Bulletin 38, 
1003-11. 
Srisurapanont, M, Suttajit, S, Maneeton, N & Maneeton, B (2015). Efficacy and 
safety of aripiprazole augmentation of clozapine in schizophrenia: a systematic 
review and meta-analysis of randomized-controlled trials. Journal of Psychiatric 
Research 62, 38-47. 
Stroup, TS, Gerhard, T, Crystal, S, Huang, C & Olfson, M (2014). Geographic and 
clinical variation in clozapine use in the United States. Psychiatric Services 65, 186-
92. 
Stroup, TS, Gerhard, T, Crystal, S, Huang, C & Olfson, M (2016). Comparative 
Effectiveness of Clozapine and Standard Antipsychotic Treatment in Adults With 
Schizophrenia. American Journal of Psychiatry 173, 166-73. 
Swets, M, Dekker, J, van Emmerik-van Oortmerssen, K, Smid, GE, Smit, F, de 
Haan, L & Schoevers, RA (2014). The obsessive compulsive spectrum in 
schizophrenia, a meta-analysis and meta-regression exploring prevalence rates. 
Schizophrenia Research 152, 458-68. 
Taipale, H, Mehtala, J, Tanskanen, A & Tiihonen, J (2017). Comparative 
Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia-A 
Nationwide Study With 20-Year Follow-up. Schizophrenia Bulletin. 
Taylor, DM, Barnes, TRE & Young, AH (2018). The Maudsley Prescribing 
Guidelines in Psychiatry. Wiley. 
Taylor, DM, Smith, L, Gee, SH & Nielsen, J (2012). Augmentation of clozapine with 
a second antipsychotic - a meta-analysis. Acta Psychiatrica Scandinavica 125, 15-
24. 
Taylor, DM, Young, C & Paton, C (2003). Prior antipsychotic prescribing in patients 
currently receiving clozapine: a case note review. Journal of Clinical Psychiatry 64, 
30-4. 
Tharyan, P & Adams, CE (2005). Electroconvulsive therapy for schizophrenia. 
Cochrane Database of Systematic Reviews. 
Tiihonen, J, Haukka, J, Taylor, M, Haddad, PM, Patel, MX & Korhonen, P (2011). 
A nationwide cohort study of oral and depot antipsychotics after first hospitalization 
for schizophrenia. American Journal of Psychiatry 168, 603-9. 
Tiihonen, J, Lonnqvist, J, Wahlbeck, K, Klaukka, T, Niskanen, L, Tanskanen, A 
& Haukka, J (2009). 11-year follow-up of mortality in patients with schizophrenia: a 
population-based cohort study (FIN11 study). Lancet 374, 620-7. 
Tiihonen, J, Mittendorfer-Rutz, E, Majak, M, Mehtala, J, Hoti, F, Jedenius, E, 
Enkusson, D, Leval, A, Sermon, J, Tanskanen, A & Taipale, H (2017). Real-World 
Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29823 Patients 
With Schizophrenia. JAMA Psychiatry 74, 686-693. 
Tollefson, GD, Birkett, MA, Kiesler, GM & Wood, AJ (2001). Double-blind 
comparison of olanzapine versus clozapine in schizophrenic patients clinically 
eligible for treatment with clozapine. Biological Psychiatry 49, 52-63. 
Ucok, A, Cikrikcili, U, Karabulut, S, Salaj, A, Ozturk, M, Tabak, O & Durak, R 
(2015). Delayed initiation of clozapine may be related to poor response in treatment-
resistant schizophrenia. International Clinical Psychopharmacology 30, 290-5. 
Verdoux, H, Quiles, C, Bachmann, CJ & Siskind, D (2018). Prescriber and 
institutional barriers and facilitators of clozapine use: A systematic review. 
Schizophrenia Research. 
Vermeulen, JM, van Rooijen, G, van de Kerkhof, MPJ, Sutterland, AL, Correll, 
CU & de Haan, L (2018). Clozapine and Long-Term Mortality Risk in Patients With 
Schizophrenia: A Systematic Review and Meta-analysis of Studies Lasting 1.1-12.5 
Years. Schizophr Bull. 
Weiser, M, Levi, L, Burshtein, S, Hagin, M, Matei, VP, Podea, D, Micluţia, I, 
Tiugan, A, Pacala, B, Grecu, IG, Noy, A, Zamora, D & Davis, JM (2017). 
Raloxifene plus antipsychotics versus placebo plus antipsychotics in severely ill 
decompensated postmenopausal women with schizophrenia or schizoaffective 
disorder: A randomized controlled trial. Journal of Clinical Psychiatry 78, e758-e765. 
Wheeler, AJ (2008). Treatment pathway and patterns of clozapine prescribing for 
schizophrenia in New Zealand. Annals of Pharmacotherapy 42, 852-60. 
Wimberley, T, MacCabe, JH, Laursen, TM, Sorensen, HJ, Astrup, A, Horsdal, 
HT, Gasse, C & Stovring, H (2017). Mortality and Self-Harm in Association With 
Clozapine in Treatment-Resistant Schizophrenia. American Journal of Psychiatry 
174, 990-998. 
Wimberley, T, Støvring, H, Sørensen, HJ, Horsdal, HT, MacCabe, JH & Gasse, C 
(2016). Predictors of treatment resistance in patients with schizophrenia: a 
population-based cohort study. The Lancet Psychiatry 3, 358-66. 
Yoshimura, B, Yada, Y, So, R, Takaki, M & Yamada, N (2017). The critical 
treatment window of clozapine in treatment-resistant schizophrenia: Secondary 
analysis of an observational study. Psychological Medicine 250, 65-70. 
Zheng, W, Xiang, YT, Yang, XH, Xiang, YQ & de Leon, J (2017). Clozapine 
Augmentation With Antiepileptic Drugs for Treatment-Resistant Schizophrenia: A 
Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Psychiatry 78, 
e498-e505. 
 
 
